Hansa Biopharma, "Hansa" and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announced initiation of GNT-018-IDES, a Phase 2 trial in ...
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.